Modified CD8 Polypeptides Enhance T Cell Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for manufacturing T cells with enhanced cytotoxic activity for immunotherapy are inadequate, as they do not effectively harness the full potential of CD8 polypeptides in conjunction with T cell receptors (TCRs) or chimeric antigen receptors (CARs).
Innovation Solution
The development of modified CD8 polypeptides that comprise specific domains such as immunoglobulin-like domains, stalk regions, transmembrane domains, and cytoplasmic domains, which are co-expressed with TCRs or CARs in T cells, enhancing their cytotoxic activity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for manufacturing T cells are used, then the process is simple, but the cytotoxic activity and effectiveness against cancer cells is insufficient
Solution Approach 1:
The patent combines CD8 polypeptides with T cell receptors or chimeric antigen receptors to create engineered T cells that co-express multiple functional components. This merging of CD8 coreceptor functionality with antigen recognition capabilities enhances cytotoxic activity while integrating multiple functions into a unified cellular therapy product
Solution Approach 2:
The patent creates composite cellular structures by engineering T cells to co-express CD8 polypeptides alongside TCRs or CARs. This composite approach combines the antigen recognition function of TCRs/CARs with the enhanced signaling and cytotoxic function of CD8, resulting in T cells with superior anti-tumor activity
2Reliability
If modified CD8 polypeptides are co-expressed with TCRs or CARs, then the cytotoxic activity is enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent merges the expression of modified CD8 polypeptides with TCR or CAR expression in the same T cell population. This is achieved through dual transduction protocols or co-expression vectors, allowing simultaneous production of multiple therapeutic components in a standardized manufacturing process
Solution Approach 2:
The patent segments the manufacturing process into distinct steps: first transducing T cells with CD8 polypeptide expression vectors, then transducing with TCR or CAR expression vectors. This segmented approach allows optimization of each transduction step independently while maintaining overall process control and scalability
Data Source
AI summary
The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.